Identification of an FGFR1 Sparing, Reversible, FGFR2 Clinical Development Candidate with Potency Against Gatekeeper and Molecular Brake Mutations – Cogent Biosciences

Skip to content

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

About
Bezuclastinib
Careers
Pipelines & Research Targets
- Pipeline
- Posters & Publications
Patients & Families
Investors & Media

Identification of an FGFR1 Sparing, Reversible, FGFR2 Clinical Development Candidate with Potency Against Gatekeeper and Molecular Brake Mutations

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

File size: 927.43 KB

Created: October 2023

Updated: October 2024

Hits: 18

Download Preview

Cogent Biosciences, Inc.

Massachusetts Office:
275 Wyman Street, 3^rd floor
Waltham, MA 02451

Boulder Office:
4840 Pearl E Circle, Suite 100
Boulder, CO 80301

About
Bezuclastinib
Careers
Pipelines & Research Targets
Patients & Families
Investors & Media
Legal
Privacy Policy
Cookie Notice

Scroll to Top

Scroll to Top